AMR Action Fund invests in BioVersys AG
The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland.
Resistell AG closes series B first tranche of CHF 8.5m
Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, based in Muttenz, Switzerland, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5m from new and existing investors.
Anokion raises USD 35m Financing
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative.
Norgine Ventures provides Debt Financing to Lunaphore
Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies.
VISCHER advised Forty51 Ventures in the closing of its first fund
VISCHER advised Forty51 Ventures, a Biotech venture capital firm, on its first fund, Forty51 Ventures Fund I SCSp, FIAR, which raised USD 43 million in a first closing and is domiciled in Luxemburg (the "Fund").
Management Buy-Out of Roventa-Henex
The management acquired 60% of the share capital of Roventa-Henex SA, a leading manufacturer of quality Swiss Made Private Label watches founded in 1959. Munich-based Findos Investor GmbH retains the remaining 40% of the share capital.
QoQa finances its craft brewery through a security token offering
QoQa Brew SA, a subsidiary of QoQa Services SA, financed its craft brewery through a security token offering.
Mosanna Therapeutics AG closes Seed Financing Round
Mosanna Therapeutics AG, a Basel-based biotechnology company developing the advanced small molecule MOS118 (formerly know as AVE0118) for the treatment of metabolic obstructive sleep apnea, closes a Seed Financing Round led by Forty51 Ventures.
ImmunOs Therapeutics AG to raise CHF 74m Series B financing
ImmunOs Therapeutics AG has agreed to a CHF 74 million Series B financing led by incoming co-lead investors Samsara Biocapital, Lightspeed Venture Partners and Gimv, corner-stoned by GL Capital, Mission BioCapital, Peak 6 Strategic Capital and Fiscus Financial
Engimmune Therapeutics AG raises CHF 15.5m in a Seed Financing
Engimmune Therapeutics AG, a biotech company based in Basel developing novel T-cell receptor (TCR)-based therapeutics, closed a CHF 15.5m seed financing round.